Sort
51,593 grants matching “hepatitis”
Host Genetic Contribution to HCV Outcomes
$519,913Ronald E. Blanton · Case Western Reserve University · R01 · FY2011 · AI
The role of hepatocyte tPA in hepatic VLDL production.
$519,897Ze Zheng · Medical College Of Wisconsin · R01 · FY2023 · HL
The role of hepatocyte tPA in hepatic VLDL production.
$519,897Ze Zheng · Medical College Of Wisconsin · R01 · FY2025 · HL
Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling
$519,896Shaodong Guo · Texas A&M Agrilife Research · R01 · FY2022 · DK
Role of inflammation, innate resistance, and immunity in carcinogenesis
$519,797Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Improving Prematurity-related Respiratory Outcomes at Vanderbilt (IMPROV)
$519,792Judy L Aschner · Albert Einstein College Of Medicine · U01 · FY2013 · HL
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease
$519,780Wenke Feng · Tulane University Of Louisiana · R01 · FY2023 · AA
Identifying and inhibiting the SARS-CoV-2 packaging mechanism
$519,750Jennifer A Doudna · J. David Gladstone Institutes · R21 · FY2021 · AI
Function of stellate cells in immunity and T cell instruction
$519,750Florian Winau · Immune Disease Institute, Inc. · R01 · FY2011 · AI
Mechanisms of Interferon-based Therapy and Resistance in HCV Infection
$519,744T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK
Cell Culture And Animal Models of HCV Infection And HCV-Host interactions
$519,744T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK
Studies into the Mechanisms for MHV Replication
$519,733University Of North Carolina Chapel Hill · R01 · FY2003 · AI
Ketone Body Metabolism and Integrated Metabolic Homeostasis
$519,723Peter A Crawford · University Of Minnesota · R01 · FY2021 · DK
Mouse and Infection Models
$519,692Sara Elizabeth Hamilton Hart · University Of Minnesota · P01 · FY2025 · AI
Intervention to Reduce Injection Drug Use
$519,610Robert E Booth · University Of Colorado Denver · R01 · FY2007 · DA
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs
$519,525Shyamasundaran Kottilil · University Of Maryland Baltimore · R01 · FY2021 · DA
The Innate Immune Response in the Marmoset Model of GBV-B Infections: A Surrogate
$519,519Robert E Lanford · Texas Biomedical Research Institute · R01 · FY2013 · AI
NEUROCOGNITIVE
$519,499Robert Kernachan Heaton · University Of California, San Diego · P01 · FY2007 · DA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
$519,480Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2019 · CA
CONTRAST-ENHANCED ULTRASOUND EVALUATION OF FOCAL LIVER LESIONS IN PATIENTS WITH CIRRHOSIS OR OTHER RISK FACTORS FOR DEVELOPING HCC
$519,465Andrej Lyshchik · Thomas Jefferson University · R01 · FY2020 · CA
Role of the Cell Adhesome in Obesity-related Liver Diseases
$519,441David H Wasserman · Vanderbilt University · R01 · FY2020 · DK
Nutrition Infection and Hepatic Carbohydrate Metabolism
$519,422Owen P McGuinness · Vanderbilt University · R01 · FY2016 · DK
Nutrition Infection and Hepatic Carbohydrate Metabolism
$519,422Owen P McGuinness · Vanderbilt University · R01 · FY2015 · DK
Nutrition Infection and Hepatic Carbohydrate Metabolism
$519,422Owen P McGuinness · Vanderbilt University · R01 · FY2017 · DK
Nutrition Infection and Hepatic Carbohydrate Metabolism
$519,422Owen P McGuinness · Vanderbilt University · R01 · FY2018 · DK